Molecular imaging of antiangiogenic agents

Oncologist

Volumn 10, Issue 2, 2005, Pages 92-103

  Rehman, Shazza ^a,b   Jayson, Gordon C ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Antiangiogenic agents; DCE MRI; Molecular imaging; Surrogate end points

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPOSTAR; CONTRAST MEDIUM; DNA; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FLUORURACIL PLUS FOLINIC ACID PLUS IRINOTECAN; INTERLEUKIN 2; RADIOISOTOPE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD FLOWMETRY; CANCER CHEMOTHERAPY; CELL HETEROGENEITY; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYTOSTASIS; DISEASE MARKER; DNA SYNTHESIS; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; GLIOMA; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; METASTASIS; MOLECULAR IMAGING; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; TUMOR VASCULARIZATION; ULTRASOUND;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, INVESTIGATIONAL; ENDOTHELIAL GROWTH FACTORS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIALS; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 13844319702     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-2-92     Document Type: Review

References (99)

1. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997;277:48-50.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
3. Boehm T, Folkman J, Browder T et al. Angiogenetic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-407.
4. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001;2:278-289.
5. Hanahan D, Folkman J. Patterns of emerging mechanisms of angiogenetic switch during tumorigenesis. Cell 1996;86:353-364.
6. Davis S, Aldrich TH, Jones PF. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-1169.
7. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
8. Los M, Voest EE. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin Oncol 2001;28:93-105.
9. Halfter W, Dong S, Schurer B et al. Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 1998;273:25404-25412.
10. Dhanabal M, Volk R, Ramchandran R et al. Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 1999;258:345-352.
11. Hohenester E, Sasaki T, Olsen BR et al. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J 1998;17:1656-1664.
12. Hurwitz H. Antiangiogenic therapy plus IFL improves survival for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003;22:3646a.
13. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-1225.
14. Westphal JR, Van't Hullenaar R, Peek R et al. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer 2000;86:768-776.
15. Morgan B, Thomas AL, Drevs J et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-3964.
16. Thorpe PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: meeting overview. Cancer Res 2003;63:1144-1147.
17. Galbraith SM. Combretastatin A4 phosphate (CA4P) reduces tumor blood flow in animals and man, demonstrated by MRI. Proc Am Soc Clin Oncol 2001;20:278a.
18. Galbraith SM, Rustin GJ, Lodge MA et al. Effects of 5,6- dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-3840.
19. Gupta N, Price PM, Aboagye EO. PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur J Cancer 2002;38:2094-2107.
20. Folkman J. Antiangiogenic therapy. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Philadelphia, PA: Lippincott-Raven Publishers, 1997:3075-3085.
21. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
22. DeVore R, Fehrenbeacher L, Herbst R et al. A randomized phase II trial comparing rhuMAB VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel chemotherapy (CRx) to CRx alone in patients with stage IIIb/IV NSCLC. Proc Am Soc Clin Oncol 2000;19:485a.
23. Kuenen BC, Rosen L, Smit EF et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002;20:1657-1667.
24. Li WW. Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol 2000;7:800-811.
25. Padhani A, Husband J. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 2001;56:607-620.
26. Brasch RC, Li KC, Husband JE et al. In vivo monitoring of tumor angiogenesis with MR imaging. Acad Radiol 2000;7:812-823.
27. Beauregard DA, Thelwall PE, Chaplin DJ et al. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998;77:1761-1767.
28. Belfi CA, Ting LL, Hassenbusch SJ et al. Determination of changes in tumor blood perfusion after hydralazine treatment by dynamic paramagnetic-enhanced magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1992;22:477-482.
29. Kennedy SD, Szczepaniak LS, Gibson SL et al. Quantitative MRI of Gd-DTPA uptake in tumors: response to photodynamic therapy. Magn Reson Med 1994;31:292-301.
30. Mayr NA, Yuh WT, Magnotta VA et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys 1996;36:623-633.
31. Parker GJ, Suckling J, Tanner SF et al. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 1997;7:564-574.
32. Su MY, Jao JC, Nalcioglu O et al. Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: studies in rat muscle tumors with dynamic Gd-DTPA enhanced MRI. Magn Reson Med 1994;32:714-724.
33. Strich G, Hagan PL, Gerber KH et al. Tissue distribution and magnetic resonance spin lattice relaxation effects of gadolinium-DTPA. Radiology 1985;154:723-726.
34. Rosen BR, Belliveau JW, Vevea JM et al. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249-265.
35. Hawighorst H, Libicher M, Knopp MV et al. Evaluation of angiogenesis and perfusion of bone marrow lesions: role of semiquantitative and quantitative dynamic MRI. J Magn Reson Imaging 1999;10:286-294.
36. Bonnerot V, Charpentier A, Frouin F et al. Factor analysis of dynamic magnetic resonance imaging in predicting the response of osteosarcoma to chemotherapy. Invest Radiol 1992;27:847-855.
37. Ostergaard M, Stoltenberg M, Lovgreen-Nielson P et al. Quantification of synovitis by MRI: correlation between dynamic and static gadolinium-enhanced magnetic resonance imaging and microscopic and macroscopic signs of synovial inflammation. Magn Reson Imaging 1998;16:743-754.
38. Galbraith SM, Lodge M, Taylor NJ et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumors: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002;15:132-142.
39. Jackson A, Jayson GC, Li KL et al. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol 2003;76:153-162.
40. Jackson A, Haroon H, Zhu X et al. Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR Biomed 2002;15:164-173.
41. Herbst RS, Mullani NA, Davis DW et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002;20:3804-3814.
42. Harte RJ, Mathews JC, O'Reilly SM et al. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L- aspartate, folinic acid, and interferon alfa. J Clin Oncol 1999;17:1580-1588.
43. Carroll VA, Glaser M, Aboagye E et al. Imaging vascular endothelial growth factor in vivo with positron emission tomography. Br J Cancer 2000;83:6.
44. Anderson H, Yap J, Price PM. Measurement of tumour and normal tissue (NT) perfusion by positron emission tomography (PET) in the evaluation of antivascular therapy: results in the phase I study of Combrestatin A4 Phosphate (CA4P). Proc Am Soc Clin Oncol 2000;19:179a.
45. 18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000;82:608-615.
46. Maisey NR, Webb A, Flux GD et al. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer 2000;83:287-293.
47. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-1782.
48. Weber WA, Haubner R, Vabuliene E et al. Tumor angiogenesis targeting using imaging agents. Q J Nucl Med 2001;45:179-182.
49. 15O: practical considerations. Nucl Med Biol 2000;27:671-676.
50. Beaney RP, Lammertsma AA, Jones T et al. Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet 1984;1:131-134.
51. Wilson CB, Lammertsma AA, McKenzie CG et al. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 1992;52:1592-1597.
52. Rhodes CG, Wise RJ, Gibbs JM et al. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 1983;14:614-626.
53. 15O and positron emission tomography: analytical techniques and preliminary results. Neuroradiology 1982;23:63-74.
54. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989.
55. Hofstra L, Liem IH, Dumont EA et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000;356:209-212.
56. Miles KA. Functional computed tomography in oncology. Eur J Cancer 2002;38:2079-2084.
57. Miles KA, Charnsangavej C, Lee FT et al. Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 2000;7:840-850.
58. Miles KA. Tumor angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol 1999;30:198-205.
59. Gillard JH, Antoun NM, Burnet NG et al. Reproducibility of quantitative CT perfusion imaging. Br J Radiol 2001;74:552-555.
60. 15O positron emission tomography. Neurol Res 2000;22:457-464.
61. Beyer T, Townsend DW, Brun T et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-1379.
62. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
63. Blomley MJ, Eckersley RJ. Functional ultrasound methods in oncological imaging. Eur J Cancer 2002;38:2108-2115.
64. Goertz DE, Christopher DA, Yu JL et al. High-frequency color flow imaging of the microcirculation. Ultrasound Med Biol 2000;26:63-71.
65. Peters-Engl C, Medl M, Mirau M et al. Color-coded and spectral Doppler flow in breast carcinomas - relationship with the tumour microvasculature. Breast Cancer Res Treat 1998;47:83-89.
66. Gee MS, Saunders HM, Lee JC et al. Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with anatomic alterations. Cancer Res 2001;61:2974-2982.
67. Ferrara KW, Merritt CR, Burns PN et al. Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. Acad Radiol 2000;7:824-839.
68. Tatum JL, Hoffman JM. Congressional update: report from the Biomedical Imaging Program of the National Cancer Institute. Imaging drug development. Acad Radiol 2000;7:1007-1008.
69. Mullani NA, Herbst RS, Abbruzzese JL et al. Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumours. Clin Positron Imaging 2000;3:151.
70. Laird AD, Vajkoczy P, Shawver LK et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000;60:4152-4160.
71. Potapova O, Laird A, Nannini M et al. Mechanism of action and biomarker studies of SU11248, a selective inhibitor of split kinase domain receptor tyrosine kinases (including VEGF receptors, PDGF receptors, c-Kit, and Flt3). Eur J Cancer 2002;38(suppl):S61.
72. Dias S, Hattori K, Zhu Z et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000;106:511-521.
73. Weng DE, Usman N. Angiozyme: a novel angiogenesis inhibitor. Curr Oncol Rep 2001;3:141-146.
74. Karumanchi SA, Jha V, Ramchandran R et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 2001;7:811-822.
75. MacDonald NJ, Shivers WY, Narum DL et al. Endostatin binds tropomyosin: a potential modulator of the antitumor activity of endostatin. J Biol Chem 2001;276:25190-25196.
76. Rehn M, Veikkola T, Kukk-Valdre E et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001;98:1024-1029.
77. Kim YM, Jang JW, Lee OH et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000;60:5410-5413.
78. Moser TL, Stack MS, Asplin I et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 1999;96:2811-2816.
79. 3 in endothelial cells. J Biol Chem 2001;276:39562-39568.
80. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 2001;19:851-856.
81. Patel SR, Jenkins J, Papadopolous N et al. Pilot study of vitaxin - an angiogenesis inhibitor - in patients with advanced leiomyosarcomas. Cancer 2001;92:1347-1348.
82. Heymach JV. Angiogenesis and antiangiogenic approaches to sarcomas. Curr Opin Oncol 2001;13:261-269.
83. Buadu LD, Murakami J, Murayama S et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996;200:639-649.
84. Stomper PC, Winston JS, Herman S et al. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat 1997;45:39-46.
85. Hawighorst H, Weikel W, Knapstein PG et al. Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 1998;4:2305-2312.
86. Buckley DL, Drew PJ, Mussurakis S et al. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging 1997;7:461-464.
87. Hulka CA, Edmister WB, Smith BL et al. Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 1997;205:837-842.
88. Tynninen O, Aronen HJ, Ruhala M et al. MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Invest Radiol 1999;34:427-434.
89. Ikeda DM, Hylton NM, Kinkel K et al. Development, standardization, and testing of a lexicon for reporting contrast-enhanced breast magnetic resonance imaging studies. J Magn Reson Imaging 2001;13:889-895.
90. Matsubayashi R, Matsuo Y, Edakuni G et al. Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 2000;217:841-848.
91. Hawighorst H, Knapstein PG, Knopp MV et al. Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 1998;58:3598-3602.
92. Knopp MV, Weiss E, Sinn HP et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999;10:260-266.
93. Cooper RA, Carrington BM, Loncaster JA et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 2000;57:53-59.
94. Nagashima T, Suzuki M, Yagata H et al. Dynamic-enhanced MRI predicts metastatic potential of invasive ductal breast cancer. Breast Cancer 2002;9:226-230.
95. Baba Y, Furusawa M, Murakami R et al. Role of dynamic MRI in the evaluation of head and neck cancers treated with radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:783-787.
96. Barentsz JO, Berger-Hartog O, Witjes JA et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 1998;207:791-797.
97. Hoskin PJ, Saunders MI, Goodchild K et al. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol 1999;72:1093-1098.
98. Devries AF, Griebel J, Kremser C et al. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res 2001;61:2513-2516.
99. Hawighorst H, Knapstein PG, Knopp MV et al. Cervical carcinoma: standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. MAGMA 1999;8:55-62.